Lacidipine

Quick links to important sections

Lacidipine

Selected form

Method of action: Hypotensive

Treatment option: Hypertension

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lacidipine

Property Description
Active Ingredient Lacidipine
Form Oral tablet (Film-coated)
Pharmacological Class Calcium Channel Blocker (CCB) / Dihydropyridine derivative
General Purpose Anti-hypertensive agent (Blood pressure management)
Origin Synthetic compound

Lacidipine: Classification and Origin

Lacidipine is a prescription-only medicine that functions as a highly selective Calcium Channel Blocker (CCB), belonging to the dihydropyridine derivative subclass. The single active ingredient is the synthetic compound Lacidipine. Its long-acting properties and high affinity for vascular tissue are clinically recognized features that distinguish it within the CCB class. This specialized action makes it suitable for sustained management.

Pharmaceutical Form and Delivery

This medication is manufactured for oral administration and is supplied as oral tablets, which are typically film-coated to ensure stability and precise delivery. Lacidipine is supplied as a single product, containing only the active ingredient along with the necessary pharmaceutical excipients required to create the stable solid dosage form. This oral format is specifically engineered to provide the gradual and consistent release needed for its established long-term effect.

Primary Role as an Anti-hypertensive Agent

The primary and well-established purpose of Lacidipine is its role as an anti-hypertensive agent intended to regulate elevated blood pressure, commonly known as systemic arterial hypertension. This benefit is achieved because Lacidipine selectively acts on the arteries to cause vasodilation (widening of blood vessels), thereby lowering systemic vascular resistance (SVR). The efficacy of Lacidipine in achieving sustained blood pressure reduction establishes the medicine as a fundamental tool for maintaining controlled vascular function.

What side effects are possible with Lacidipine?

Lacidipine: Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Lacidipine, based on governmental regulatory information. Side effects are classified by frequency and the body system affected, providing a structured overview of the medicine’s established safety profile.


Frequency-Classified Adverse Reactions

The most frequent adverse reactions are classified as Common (occurring in less than 1 in 10 patients but at least 1 in 100). These are often linked to the drug’s vasodilating effect and include headache, dizziness, flushing (reddening of the skin), oedema (swelling), palpitations, and tachycardia (increased heart rate). These effects are noted in regulatory documents to be frequently observed at the start of treatment or upon a dose increase and may be transient.

Less frequent, Uncommon reactions (1/1,000 to < 1/100) include nausea, rash, pruritus, syncope, and hypotension. Rare reactions (1/10,000 to < 1/1,000) documented by regulatory authorities include gum hyperplasia and a transient increase in liver transaminases.


Special Safety Considerations

The official labeling documents specific constraints regarding patient health status. Lacidipine is generally Contraindicated in individuals with known hypersensitivity to the drug or other dihydropyridines, those with severe aortic stenosis, and those within one month of a myocardial infarction.

Caution is required for patients with hepatic impairment, as the drug's effect may be enhanced, and in patients with a history of poor cardiac reserve. The safety and efficacy of Lacidipine have not been established for use in pediatric patients (under 18 years of age).

Overdose and Emergency Response

Overdose and when to seek help

The information regarding overdose is strictly based on documented descriptions from government regulatory sources. Overdosage with Lacidipine has no specific antidote known, meaning management focuses on supportive care.


Documented Overdose Manifestations

Property Official Regulatory Statement
Expected Physiological Effect Prolonged peripheral vasodilation is the primary expected consequence.
Expected Clinical Signs Manifestations are expected to be associated with hypotension (low blood pressure) and tachycardia (fast heart rate).
Potential Severe Outcomes Bradycardia (slow heart rate) or prolonged atrioventricular (AV) conduction impairment are severe cardiac effects that could theoretically occur.

Required Emergency Actions

When to Seek Urgent Help: The occurrence of any severe, expected cardiovascular manifestation, particularly profound hypotension or signs of impaired cardiac conduction, mandates immediate clinical assessment and management.

Officially Described Procedures: Management requires using standard general measures for monitoring cardiac function and administering appropriate symptomatic and supportive treatment to counteract the effects of excessive vasodilation.

Therapeutic Uses of Lacidipine

Main Uses of Lacidipine

Lacidipine is a medication belonging to the class of drugs known as calcium channel blockers, specifically the dihydropyridine group. Its primary clinical application is in the management of cardiovascular conditions characterized by elevated blood pressure.

Essential Hypertension

The most common use for lacidipine is the treatment of essential hypertension, also known as primary hypertension. This is a condition where blood pressure remains consistently high without a single identifiable cause. Lacidipine helps to lower blood pressure by acting on the smooth muscle cells of the peripheral blood vessels.

Mechanism of Action

Lacidipine works by inhibiting the influx of calcium ions through specific channels in the cell membranes of vascular smooth muscle. By blocking these calcium channels, the medication promotes vasodilation—the widening of the blood vessels. This process reduces peripheral vascular resistance, allowing blood to flow more easily and effectively lowering systemic blood pressure.

Benefits of Treatment

Managing hypertension with lacidipine provides several long-term health benefits centered on cardiovascular protection.

  • Blood Pressure Stability: Lacidipine is known for its long duration of action, which typically allows for consistent blood pressure control over a 24-hour period with a single daily dose.
  • Vascular Protection: Beyond its pressure-lowering effects, the medication may assist in maintaining the health of the arterial walls by reducing the mechanical stress caused by high blood pressure.
  • Reduction of Cardiovascular Risk: By maintaining blood pressure within a healthy range, the use of lacidipine helps to decrease the long-term risk of complications associated with hypertension, such as heart disease and stroke.
  • High Lipophilicity: Due to its chemical structure, lacidipine is highly lipophilic (fat-soluble), which allows it to integrate into the cell membranes of blood vessels, contributing to its prolonged and gradual onset of action.

Eligibility and Restrictions for Use

Lacidipine's use is officially documented for adults managing essential hypertension, including the older adult population, where regulatory labeling states no dose modification is generally required. The medicine is not recommended for children and adolescents under 18 years of age because safety and effectiveness in this group have not been established.


Absolute Contraindications

Lacidipine must not be used in certain patient populations as defined by regulatory labeling:

  • Patients with known hypersensitivity to lacidipine or to any other dihydropyridine calcium channel blocker.
  • Individuals diagnosed with severe aortic stenosis.
  • Patients who have experienced a myocardial infarction within the last month.

Use Restrictions and Cautions

Specific conditions require caution or conditional use as stated in official documents:

Condition Regulatory Status
Impaired Liver Function (Hepatic) Use with caution as the anti-hypertensive effect may be increased.
Cardiac Reserve/QT Prolongation Use with caution; discontinuation is required if unstable angina pectoris develops.
Pregnancy/Lactation Not recommended; use is conditional, only if the benefit outweighs the potential risk.

Use is not restricted by renal impairment, as official labeling confirms dose modification is not required for kidney function.

What should I know about interactions with other medicines?

Lacidipine Interactions with other medicines and products

The following table summarizes the officially documented interaction patterns for Lacidipine, based strictly on government regulatory sources.


Interaction Scope

Feature Documented Regulatory Information
Medicinal product categories with documented interactions Strong CYP3A4 inhibitors, Strong CYP3A4 inducers, Other Antihypertensive Agents, Anesthetics, Medications known to prolong the QT interval.
Specific interacting medicines (if explicitly listed) Itraconazole, Erythromycin, Cimetidine, Rifampicin, Simvastatin.
Mechanistic basis of interactions Metabolism primarily via CYP3A4 (leading to pharmacokinetic interactions); Additive hypotensive effects (pharmacodynamic).
Population-specific interaction notes Hepatic Impairment: Potential for enhanced hypotensive effect due to increased bioavailability.
Interaction-related restrictions Should not be taken with grapefruit juice (bioavailability may be altered).

Official Interaction Statements

  • Co-administration with strong CYP3A4 inhibitors (e.g., Itraconazole, Erythromycin) may increase the plasma concentration of Lacidipine.
  • Co-administration with strong CYP3A4 inducers (e.g., Rifampicin) may reduce the bioavailability and plasma levels of Lacidipine.
  • Concurrent use with other antihypertensive agents (e.g., Diuretics, Beta-blockers) may result in an additive hypotensive effect.
  • Lacidipine has been documented to increase the Cmax and AUC of Simvastatin when co-administered.
  • Caution is advised when used concomitantly with Anesthetics (risk of hypotension) and medications known to prolong the QT interval.

The regulatory profile highlights that Lacidipine’s interaction structure is centered on its CYP3A4-dependent metabolism, necessitating attention when combined with agents that modify enzyme activity. The profile also notes pharmacodynamic interactions resulting in additive blood pressure reduction when combined with other hypotensive drugs. These statements define the restrictions and necessary monitoring described in official prescribing information.

Mechanism of Action

Mechanism of Action: How Lacidipine Works

Lacidipine is a dihydropyridine calcium channel blocker that acts as a selective antagonist on L-type voltage-gated calcium channels primarily located in the membranes of vascular smooth muscle cells. By binding to the channel, the drug prevents the influx of extracellular calcium ions (Ca^2+) into the cell.

This molecular interaction interrupts the excitation-contraction coupling pathway. The reduced availability of intracellular calcium interferes with the activity of regulatory enzymes, which in turn leads to the relaxation of the smooth muscle fibers surrounding the peripheral arteries.

This cascade results in vasodilation (widening of the blood vessels) and a consequent reduction in total peripheral resistance (TPR) throughout the circulatory system. This physiological modulation is determined by the drug’s distinct mechanistic selectivity for the vascular tissue.

Dosage and Administration Information

How to Use Lacidipine: Administration Guidelines

Lacidipine is a prescription medicine administered exclusively through the oral route as a film-coated tablet. This medication is taken once daily and is typically used as part of a long-term therapeutic protocol for hypertension. To maintain consistent plasma levels, the tablet should be ingested at the same time each day, preferably in the morning.


Standard Dosing Regimen

The treatment protocol begins with a low dose that is gradually adjusted based on the required response. The standard dosing instructions are detailed in the product labeling:

Dosing Parameter Instruction
Initial Dose 2 mg once daily
Maintenance Range 2 mg to 6 mg once daily
Maximum Dose 6 mg once daily
Titration Interval Dose increase should occur only after a minimum of 3 to 4 weeks.

Administration Requirements

Patients may take lacidipine with or without food. However, the labeling prohibits the co-ingestion of this medication with grapefruit juice.

Population-Specific Use

For patients with renal impairment, no dose modification is required. For patients with hepatic impairment, careful monitoring is necessary, and a dose reduction may be needed in severe cases. Safety and dosing have not been established for children and adolescents under 18 years of age.

Recent Clinical Evidence

Research evidence / Overview of studies for Lacidipine


Evidence for the Management of Essential Hypertension

Research has focused extensively on exploring Lacidipine in the context of high blood pressure, known as essential hypertension. The foundation of this evidence includes numerous Randomized Controlled Trials (RCTs) and meta-analyses. These studies primarily examined adults with mild to moderate forms of the condition. Researchers structured these trials to monitor outcomes related to physiological strain, comparing Lacidipine to an inactive substance (placebo) and other established anti-hypertensive drug classes.

The trials explored short-term changes, focusing on defined observation intervals where blood pressure was monitored. Research highlights the measured change in both Systolic and Diastolic Blood Pressure (SBP/DBP) during the study period. However, evidence remains limited regarding whether Lacidipine was associated with statistically distinct outcomes compared to other established medications regarding major cardiovascular event rates, such as stroke or heart attack. While studies monitored these serious outcomes, data show patterns that were consistent with those observed between the different drug classes studied.


Studies on Vascular Structure and Related Outcomes

Beyond its exploration in blood pressure contexts, research has examined patterns related to Lacidipine and the physical structure of blood vessels. One large, long-term study was observed in patients with established hypertension who also had evidence of asymptomatic thickening in the carotid arteries. This research examined outcomes related to systemic or functional imbalance over four years.

Studies monitored a vascular measure called Carotid Intima-Media Thickness (IMT). IMT is a finding that monitors a physical change in blood vessel walls. Certainty remains low for the vascular outcomes, as the key finding related to the IMT measurement in the full trial population did not meet the pre-specified criterion for statistical certainty, meaning the finding is based primarily on a surrogate marker.


Research in Specific Patient Groups and Gaps

Studies have explored the use of Lacidipine in specific patient groups, including older adults (typically aged 60 years and above) and those with Isolated Systolic Hypertension (ISH). Furthermore, studies explored treatment in patients with hypertension who also had concurrent Type 2 Diabetes Mellitus. The overall certainty regarding differences in outcomes in complex or unstable conditions is constrained by the design of existing long-term studies.

The body of research, while extensive for exploring blood pressure outcomes, still contains specific limitations. There is limited information for long-term outcomes regarding statistical superiority over other established drug classes in relation to major clinical events, and there is a lack of research exploring outcomes in pediatric populations.

Frequently Asked Questions (FAQ)

Common questions about Lacidipine (FAQ)


Q: What is the difference between Lacidipine and Amlodipine?

Both Lacidipine and Amlodipine belong to the dihydropyridine class of calcium channel blockers. Official regulatory documentation confirms that both medications work by widening blood vessels to lower blood pressure. While they share common vasodilating side effect themes like headache and flushing, direct comparative claims regarding overall effectiveness are not typically featured in standard product labeling.


Q: What kind of studies have been done on Lacidipine?

Research on Lacidipine has focused mainly on its use for essential hypertension (high blood pressure) and includes numerous Randomized Controlled Trials (RCTs). Studies have also explored its use in specific groups, such as older adults and patients with Type 2 Diabetes Mellitus. Furthermore, some research has examined its potential effects on the physical structure of blood vessel walls.


Q: What is the typical long-term use expectation for Lacidipine?

Lacidipine is officially described as being part of a long-term therapeutic protocol for managing high blood pressure. Treatment with this medication is generally intended to be continuous to help maintain blood pressure control over time, unless a healthcare professional advises otherwise.


Q: Is it true that Lacidipine is less likely to cause ankle swelling than some other drugs in its class?

Regulatory documentation lists oedema (swelling), particularly of the ankles or feet, as a Common side effect of Lacidipine, which is an effect noted for many calcium channel blockers. While some external studies may suggest variability in the occurrence of swelling across the drug class, the official labeling for Lacidipine lists it as a common, expected effect.


Q: Does Lacidipine cause weight gain or weight loss?

Detailed regulatory safety listings have included both weight gain and weight decrease as possible side effects associated with the drug. These effects are generally classified as uncommon or very rare based on the available data.


Q: Is it normal to feel dizzy when first starting Lacidipine?

Dizziness is listed in official documentation as a Common side effect of Lacidipine. These effects are noted to be frequently observed when treatment first begins and may be temporary.


Q: Can Lacidipine tablets be split or crushed?

Lacidipine is supplied as a film-coated tablet. Standard regulatory guidelines usually instruct the patient to swallow the tablets whole with a drink of water. There are typically no provisions documented in official administration instructions for physically altering or splitting the tablet.


Q: What happens if a dose of Lacidipine is missed?

Official patient information states that if a dose is forgotten, it should be taken as soon as it is remembered. However, if it is nearly time for the next dose, the official instruction is to omit the missed dose. Official guidelines strongly advise against taking two doses together to compensate for a forgotten one.


Q: Can Lacidipine affect sleep or cause insomnia?

Detailed regulatory adverse reaction listings have included insomnia (difficulty sleeping) among the uncommon side effects associated with Lacidipine.


Q: Are there any specific foods to avoid while taking Lacidipine?

The only specific food product restriction consistently documented in the official labeling is that the medicine should not be taken with grapefruit juice. Grapefruit juice may alter the way the drug is processed in the body.


Q: Is Lacidipine safe for older adults or the elderly?

Official regulatory labeling documents Lacidipine for use in adults, including the older adult population. The prescribing information confirms that generally no dose adjustment is required based solely on the patient's age.


Q: Is Lacidipine a vasodilator?

Yes. Lacidipine’s mechanism of action is described in regulatory documents as causing vasodilation (widening of blood vessels) by relaxing the peripheral arteries. This physiological action helps achieve its effect of lowering blood pressure.


Q: Can I take pain relievers like Ibuprofen or Aspirin with Lacidipine?

Regulatory documentation notes that caution is advised regarding co-administration with NSAIDs (Non-Steroidal Anti-Inflammatory Drugs, such as Ibuprofen). Specific interaction data has addressed the concomitant use of these classes, noting an increased risk of gastrointestinal hemorrhage when taken with calcium channel blockers.


Q: Is there any research on Lacidipine for people with existing heart conditions?

Research has explored Lacidipine's use in patients with hypertension who also have heart-related issues such as Isolated Systolic Hypertension (ISH). Official labeling, however, lists certain heart conditions, like severe aortic stenosis or a recent myocardial infarction, as conditions where the medicine is generally restricted or use requires specific caution.


Q: Are there different strengths or doses of Lacidipine?

Yes. Official product information indicates that Lacidipine tablets are typically supplied in multiple physical strengths, often including 2 mg, 4 mg, and 6 mg tablets.


Q: Does Lacidipine have any reported long-term side effects?

Official documentation classifies adverse reactions based on how often they occur (e.g., Common, Uncommon). These classifications cover the period of use, but regulatory text does not typically distinguish between short-term versus those that persist or only emerge after prolonged long-term use.


Q: Does taking Lacidipine affect cholesterol levels?

Lacidipine is a medication for blood pressure, not specifically for lipid management. However, research has explored themes related to its action on blood vessel walls and its connection to cholesterol metabolism and the development of atherosclerosis.


Q: Does Lacidipine interact with blood thinners?

Official interaction studies have generally reported no specific problems when Lacidipine is used with common blood thinners, such as Warfarin. Official prescribing information notes that concurrent use requires general attention.


Q: Can Lacidipine cause a persistent dry cough?

While dry cough is a known side effect of some other blood pressure medicines, regulatory adverse reaction listings for Lacidipine have included cough as an uncommon side effect.


Q: What is the half-life of Lacidipine?

According to official pharmacological data, the terminal elimination half-life of Lacidipine is described as ranging from 13 to 19 hours. This figure indicates the time it takes for half of the medication to be eliminated from the body.


Q: Is Lacidipine generally well-tolerated?

Official safety documents list the most frequent side effects as Common (up to 1 in 10 patients), such as temporary effects like headache and dizziness. Based on this information, official information suggests a generally expected tolerability profile.


Q: Does Lacidipine contain lactose or other common allergens?

Yes, official product information lists the inactive ingredients, or excipients, used in the tablet. These regulatory lists confirm that Lacidipine tablets contain lactose monohydrate.

How should Lacidipine be stored and disposed of?

How to Store and Dispose of Lacidipine

The storage and disposal requirements for lacidipine are defined by regulatory labeling to maintain the product's stability and ensure safety.

Storage & Handling Requirement Official Instruction
Protection Store in the original package in order to protect from light.
Usage Restriction Do not use the medicine after the expiry date stated on the carton.
Child Safety Keep out of the sight and reach of children.
Disposal Do not throw away unused medicine via wastewater or household waste. Dispose of the medicine through a pharmacist or according to local requirements to protect the environment.

Lacidipine tablets must remain in their original blister packaging until needed for administration. The overall profile focuses on light protection and strict adherence to the stated shelf-life.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lacidipine found in:

A-Z Index: